| |
- M. Sato, Z. Fang, M.K. Fukuda, Y. Fukui, K. Futatsukawa, K. Ikegami, H. Kobayashi, C. Kubota, T. Kurihara, T. Miura, T. Miyajima, F. Naito, K. Nanmo, T. Obina, T. Shibata, T. Sugimura, A. Takagi
KEK, Ibaraki, Japan
- H. Kumada, Y. Matsumoto, Su. Tanaka
Tsukuba University, Graduate School of Comprehensive Human Sciences, Ibaraki, Japan
- N. Nagura, T. Ohba
Nippon Advanced Technology Co., Ltd., Tokai, Japan
- H. Oguri
JAEA/J-PARC, Tokai-mura, Japan
- T. Toyoshima
ATOX, Ibaraki, Japan
|
|
| |
An accelerator-based boron neutron capture therapy (BNCT) has been studied intensively in recent years as one of the new cancer therapies after many clinical research with nuclear reactors. In the iBNCT project, the accelerator configuration consists of an RFQ and a DTL which have proven achievements in J-PARC. Meanwhile, a high duty factor is required to have a sufficient thermal neutron flux needed by BNCT treatments. After a failure of the klystron power supply occurred in Feb. 2019, beam operation was resumed in May 2020. To date, an average current of about 2 mA with the beam repetition rate of 75 Hz has been achieved with stable operation. Irradiation tests with cells and mice are ongoing together with characteristic measurements of the neutron beam. In parallel with that, we have been gradually improving the accelerator cooling-water system for further stability. In this contribution, the present status and prospects of the iBNCT accelerator are reported.
|
|
